Updated May 30, 2026, 4:23 PM
AntiinfectiveUS FDA Database Verified

levofloxacin (Rx)

Generic: Levofloxacin

Brand: Levaquin

(lev-o-floks'a-sin)

Pregnancy Category: C

Pharmacological Action

Interferes with conversion of intermediate DNA fragments into high molecular weight DNA in bacteria; DNA gyrase inhibitor; inhibits topoisomerase IV

Therapeutic outcome: Bacteriocidal action against the following: Streptococcus pneumoniae, Haemophilus influenzae, Haemophilus parainfluenzae, Moraxella catarrhalis, Klebsiella pneumoniae, Mycoplasma pneumoniae, Escherichia coli, Serratia marcescens, Chlamydia pneumoniae, Legionella pneumophilia, Enterococcus faecalis, Staphylococcus epidermidis, Staphylococcus pyogenes

Uses

Acute sinusitis, acute chronic bronchitis, community-acquired pneumonia, uncomplicated skin infections, UTI, cellulitis, prostatitis, inhalational anthrax (postexposure), acute pyelonephritis, inhalation anthrax in children

Contraindications

Hypersensitivity to quinolones

Precautions: Pregnancy C, breastfeeding, children; photosensitivity, acute MI, atrial fibrillation, colitis, dehydration, diabetes, QT prolongation, myasthenia gravis, renal disease, seizure disorder, syphilis

BLACK BOX WARNING: Tendon pain/rupture, tendinitis

Dosage & Routes

Acute bacterial exacerbation of chronic bronchitis

Adult: PO/IV 500 mg q24 hr × 7 days Acute bacterial sinusitis

Adult: PO 500 mg q24 hr × 10-14 days or 750 mg q24 hr × 5 days Mild-moderate UTI/acute pyelonephritis

Adult: PO/IV 750 mg q24 hr × 5 days or 250 mg q24 hr × 10 days Chronic bacterial prostatitis

Adult: PO 500 mg q24 hr × 28 days Postexposure inhalational anthrax Adult/adolescent/child >50 kg: PO/IV 500 mg q24 hr × 60 days Infant >6 mo and child <50 kg: IV 8 mg/kg q12 hr × 60 days, max 250 mg/dose Pneumonia, community acquired

Adult: PO/IV 500 mg q24 hr × 7-14 days or 750 mg q24 hr × 5 days Pneumonia, nosocomial

Adult: PO/IV 750 mg q24 hr × 7-14 days SSSI, complicated

Adult: PO/IV 750 mg q24 hr × 7-14 days SSSI, uncomplicated

Adult: PO 500 mg q24 hr × 7-10 days UTI, complicated

Adult: PO/IV 750 mg q24 hr × 5 days or 250 mg q24 hr × 10 days UTI, uncomplicated

Adult: PO 250 mg q24 hr × 3 days Plague (Yersinia pestis)

Adult: PO/IV 500 mg q24 hr × 10-14 days (with pneumonia, 750 mg q24 hr) Adolescent/child <50 kg: PO/IV 8 mg/kg (max 250 mg/dose) q12 hr × 10-14 days Renal disease

Adult: PO/IV CCr 20-49 ml/min: for 750-mg dose, give 750 mg q48 hr; for 500-mg dose, give 500 mg once, then 250 mg q24 hr; for 250-mg dose, no adjustment; CCr 10-19 ml/min: for 750-mg dose, give 750 mg once, then 500 mg q48 hr; for 500-mg dose, give 500 mg once, then 250 mg q48 hr; for 250-mg dose, give 250 mg q48 hr, except when treating complicated UTI, then no dose adjustment

Available forms: Single-use vials (500, 750 mg), premixed flexible container; 250 mg/50 ml D5 W, 500 mg/100 ml D5 W, 750 mg/150 ml D5 W; tabs 250, 500, 750 mg; oral sol 25 mg/ml

Implementation - Obtain C&S before treatment and periodically - Give PO 2 hr before or 2 hr after antacids, iron, calcium, zinc; give fluids - Check for irritation, extravasation, phlebitis daily Oral solution: - Give 1 hr prior to or 2 hr after food

Intermittent IV infusion route: - Discard any unused sol in the single-dose vial - Visually inspect for particulate matter/discoloration prior to use IV (single use vial): - 500 mg/20 ml vials: To prepare a dose of 500 mg, withdraw 10 ml from a 20-ml vial and dilute with a compatible IV solution (D5 W, NS) to a total volume of 50 ml. To prepare a 500-mg dosage, withdraw all 20 ml from the vial and dilute with a compatible IV solution to a total volume of 100 ml - 750 mg/30 ml vials: To prepare a dose of 750 mg, withdraw 30 ml from a 30-ml vial and dilute with a compatible intravenous solution (D5 W, NS) to a total volume of 150 ml - The concentration of the diluted solution should be 5 mg/ml prior to administration. Solutions contain no preservatives; any unused portions must be discarded -

Storage: The diluted solution may be stored for up to 72 hours when stored at or below 25° C (77° F) or for 14 days when stored under refrigeration at 5° C (41° F) in plastic containers. Solutions may be frozen for up to 6 months (-20° C or -4° F) in glass bottles or plastic containers. Thaw frozen solutions at room temperature (25° C or 77° F) or in a refrigerator (8° C or 46° F). Do not force thaw by microwave or water bath immersion. Do not refreeze after initial thawing Premixed IV solution: - No dilution is necessary Intermittent IV injection: - Infuse doses of ≤500 mg IV over 60 minutes and doses of 750 mg IV over 90 minutes. Shorter infusions or bolus injections should be avoided because of the risk of hypotension

Y-site compatibilities: Alemtuzumab, alfentanil, amifostine, amikacin, aminocaproic acid, aminophylline, ampicillin, ampicillin-sulbactam, anidulafungin, argatroban, atenolol, atracurium, aztreonam, bivalirudin, bleomycin, bumetanide, buprenorphine, busulfan, butorphanol, caffeine citrate, calcium gluconate, CARBOplatin, carmustine, caspofungin, cefepime, cefoTEtan, ceftaroline, cefTAZidime, ceftizoxime, cefTRIAXone, cefuroxime, chlorproMAZINE, cimetidine, cisatracurium, CISplatin, clindamycin, codeine, cyclophosphamide, cycloSPORINE, cytarabine, dacarbazine, DACTINomycin, DAPTOmycin, DAUNOrubicin liposomal, dexamethasone, dexrazoxane, digoxin, diltiazem, diphenhydrAMINE, DOBUTamine, DOCEtaxel, dolasetron, DOPamine, doripenem, doxacurium, doxycycline, droperidol, enalaprilat, ePHEDrine, EPINEPHrine, epirubicin, ertapenem, erythromycin, esmolol, etoposide, etoposide phosphate, famotidine, fenoldopam, fentaNYL, filgrastim, floxuridine, fluconazole, fludarabine, foscarnet, fosphenytoin, gallium, gemcitabine, gemtuzumab, gentamicin, granisetron, haloperidol, hydrocortisone, HYDROmorphone, IDArubicin, ifosfamide, imipenem-cilastatin, irinotecan, isoproterenol, labetalol, lepirudin, leucovorin, levorphanol, lidocaine, linezolid, mannitol, mechlorethamine, meperidine, mesna, methylPREDNISolone, metoclopramide, metroNIDAZOLE, midazolam, milrinone, minocycline, mitoMYcin, mitoXANtrone, mivacurium, morphine, mycophenolate mofetil, nalbuphine, naloxone, nesiritide, netilmicin, niCARdipine, octreotide, ondansetron, oxacillin, oxaliplatin, oxytocin, PACLitaxel, palonosetron, pamidronate, pancuronium, PEMEtrexed, penicillin G sodium, pentamidine, phenylephrine, plicamycin, potassium acetate/chloride, promethazine, propranolol, quinupristin-dalfopristin, ranitidine, remifentanil, rocuronium, sargramostim, sodium bicarbonate, succinylcholine, SUFentanil, sulfamethoxazole-trimethoprim, tacrolimus, teniposide, theophylline, thiotepa, ticarcillin, ticarcillin-clavulanate, tigecycline, tirofiban, tobramycin, topotecan, trimethobenzamide, vancomycin, vasopressin, vecuronium, verapamil, vinBLAStine, vinCRIStine, vinorelbine, voriconazole, zidovudine, zoledronic acid Solution compatibilities: 0.9% NaCl, D5 W, D5/0.9% NaCl, D5 LR, D5/0.45% NaCl, sodium lactate, plasma-lyte 56/D5 W

Adverse Effects

CNS: Headache, dizziness, insomnia, anxiety, seizures, encephalopathy, paresthesia, pseudotumor cerebri

CV: Chest pain, palpitations, vasodilatation, QT prolongation, hypotension (rapid infusion)

EENT: Dry mouth, visual impairment, tinnitus

GI: Nausea, flatulence, vomiting, diarrhea, abdominal pain, pseudomembranous colitis, hepatotoxicity, esophagitis, pancreatitis

GU: Vaginitis, crystalluria

HEMA: Eosinophilia, hemolytic anemia, lymphophemia

INTEG: Rash, pruritus, photosensitivity, epidermal necrolysis, injection site reaction, edema

MISC: Hypoglycemia, hypersensitivity, tendon rupture, rhabdomyolysis

RESP: Pneumonitis

SYST: Anaphylaxis, multisystem organ failure, Stevens-Johnson syndrome, angioedema, toxic epidermal necrolysis

Pharmacokinetics

Absorption: Unknown

Distribution: Unknown

Excretion: Kidneys unchanged

Half-life: 6-8 hr

Pharmacodynamics

Onset: Immediate

Peak: Infusion’s end

Duration: Unknown

Interactions

Individual drugs Calcium, iron, sucralfate, zinc: decreased absorption of levofloxacin

Foscarnet: increased CNS stimulation, seizures Haloperidol, chloroquine, droperidol, pentamidine, arsenic trioxide, levomethadyl: increased QT prolongation

Magnesium: decreased levofloxacin absorption; do not use in same IV line

Probenecid: increased levofloxacin levels

Theophylline: decreased theophylline clearance; toxicity may result

Warfarin: increased bleeding

Drug classifications Antacids (magnesium, aluminum): decreased absorption of levofloxacin

BLACK BOX WARNING:

Corticosteroids: increased tendon rupture Class IA/III antidysrhythmics, some phenothiazines, beta agonists, local anesthetics, tricyclics, CYP3 A4 inhibitors (amiodarone, clarithromycin, erythromycin, telithromycin, troleandomycin), CYP3 A4 substrates (methadone, pimozide, QUEtiapine, quiNIDine, risperidone, ziprasidone): increased QT prolongation NSAIDs, cycloSPORINE: increased CNS stimulation, seizures

Drug/lab test

Increased: PT, INR

Decreased: glucose, lymphocytes

Nursing Considerations

Assessment - Assess patient for previous sensitivity reaction to quinolones - Assess patient for signs and symptoms of infection, including characteristics of wounds, sputum, urine, stool, WBC >10,000/mm3, fever; baseline, during treatment - Obtain C&S before beginning product therapy to identify if correct treatment has been initiated - QT prolongation: Monitor for QT prolongation, ejection fraction; assess for chest pain, palpitations, dyspnea - Pseudomembranous colitis: Assess for diarrhea, abdominal pain, fever, fatigue, anorexia; possible anemia, elevated WBC and low serum albumin; stop product and give usually either vancomycin or IV metroNIDAZOLE - Assess for allergic reactions and anaphylaxis: rash, urticaria, pruritus, chills, fever, joint pain; may occur a few days after therapy begins; epinephrine and resuscitation equipment should be available for anaphylactic reaction - Determine urine output; if decreasing, notify prescriber (may indicate nephrotoxicity); also check for increased BUN, creatinine - Monitor blood tests: AST, ALT, CBC, Hct, bilirubin, LDH, alkaline phosphatase, Coombs’ test monthly if patient is on long-term therapy - Monitor electrolytes: potassium, sodium, chloride monthly if patient is on long-term therapy - Monitor for bleeding: ecchymosis, bleeding gums, hematuria, stool guaiac daily if on long-term therapy - Assess for overgrowth of infection: perineal itching, fever, malaise, redness, pain, swelling, drainage, rash, diarrhea, change in cough, sputum

BLACK BOX WARNING: Tendon rupture: Discontinue product at first sign of tendon pain or inflammation; usually the Achilles tendon is affected, can occur up to a few months after treatment and may require surgical repair; steroids may increase risk

Patient/family education - Teach patient to report sore throat, bruising, bleeding, joint pain; may indicate blood dyscrasias (rare) - Advise patient to contact prescriber if vaginal itching, loose foul-smelling stools, furry tongue occur, may indicate superinfection; report itching, rash, pruritus, urticaria - Instruct patient to take all medication prescribed for the length of time ordered; product must be taken around the clock to maintain blood levels; do not give medication to others - Advise patient to notify prescriber of diarrhea with blood or pus - Instruct patient to take 2 hr before antacids, iron, calcium, zinc products - Tell patient to complete full course of therapy; to increase fluid intake to 2 L/day to prevent crystalluria - Advise patient to avoid hazardous activities until response to product is known - Instruct patient to rinse mouth frequently and use sugarless candy or gum for dry mouth - Instruct patient to avoid taking other medications unless approved by prescriber - Teach patient to monitor glucose (diabetes) - Advise patient to avoid sun exposure or use sunscreen to prevent phototoxicity

BLACK BOX WARNING: Teach patient to notify prescriber of tendon pain, inflammation, avoid corticosteroids with this product

Evaluation

Positive therapeutic outcome: Absence of signs/symptoms of infection (WBC <10,000/mm3, temp WNL); Reported improvement in symptoms of infection

Reference

Mosby's Drug Guide; Davis Drug Guide

Need clinical tools for this drug?

Save notes, bookmark this drug, and run formula method (desire over have) dosage calculations all inside the KosPharm Dashboard.

One-time payment. No subscription. No recurring charges.

Sign in to Get Full Access